Seelos Therapeutics

Corporate moves

iX Biopharma aims for stronger growth momentum with Seelos licensing deal

iX Biopharma announces an outlicensing agreement worth more than $300 million (excluding royalties) with Seelos Therapeutics
iX Biopharma inks exclusive agreement with Seelos worth up US$239 mil - THE EDGE SINGAPORE

Healthcare

iX Biopharma inks exclusive agreement with Seelos worth up US$239 mil

iX Biopharma will also receive double digit percentage royalties on future net sales of any licensed product.
×